PDCD1 and head and neck squamous cell carcinoma: Interruption of PD-1/PD-L1-mediated immune evasion by monoclonal antibodies is the basis of modern immune checkpoint inhibitors (ICI) and represents a major therapeutic breakthrough, particularly in metastatic and recurrent HNSCC (9).